A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

Inclusion Criteria: * Understand the study and agree to participate. * Be available for follow-up visits and contact for 12 months after the last study product is administered. * Be willing to undergo all study procedures. * Not be in another study unless approved by both study sponsors. * Be in good general health. * Have normal physical exam and lab results. * Agree to discuss HIV risk and prevention. * Have a certain minimum hemoglobin level (≥ 11.0 g/dL for women, ≥ 13.0 g/dL for men). * Have a white blood cell count within 2500 to 12,000/mm³. * Have a platelet count between 125,000 to 550,000/mm³. * Have an ALT level less than 2.5 times the upper limit of normal. * Have a serum creatinine level within 1.1 times the normal limit. * Have a serum calcium level of at least 8.5 mg/dL. * Have blood pressure within specified limits. * Test negative for HIV. * Test negative for Hepatitis C. * Test negative for Hepatitis B. * Women who can become pregnant must use effective contraception and test negative for pregnancy at enrollment. * Women who can become pregnant must agree not to seek pregnancy through alternative methods during the study period. Exclusion Criteria: * Breastfeeding or pregnant. * BMI is 40 or higher (exceptions can be made if you're in good health). * Diagnosed with diabetes (unless it's well-controlled Type 2 diabetes or gestational diabetes). * Received an investigational HIV vaccine or monoclonal antibodies. * Received a non-HIV investigational vaccine in the past year (exceptions exist for licensed or emergency-authorized vaccines). * Have an immune deficiency or are taking medications that impair immune response. * Received blood products or immunoglobulins within the last 16 weeks. * Received certain vaccines within 4 weeks before enrollment. * Received other vaccines within 14 days before enrollment. * Started allergy immunotherapy within the last year (stable therapy is okay). * Taken investigational research agents recently. * Had a serious reaction to any vaccine. * Have hereditary or acquired angioedema. * Had unexplained hives in the past year. * Have a bleeding disorder that would make study procedures risky. * Had seizures or taken seizure medication in the past 3 years. * Spleen has been removed or spleen doesn't work properly. * Active duty or reserve US military personnel. * Any serious health condition that could affect safety, rights, or ability to participate (including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential recurrence). * Asthma that requires frequent or high-dose medication, emergency care, or multiple maintenance therapies. * History of certain immune-mediated medical conditions (mild, localized conditions may be okay). * Allergic to local anesthetics like Novocaine or Lidocaine. * History of difficult venous access or intravenous drug use.